Zim Laboratories Ltd Q4 FY26 Results

Summary

Zim Laboratories Limited reported a decline in financial performance for both Q4 and the full fiscal year FY26. For the full year, total operating income decreased by 1.2% to ₹3,744 Mn, while EBITDA fell by 16.4% to ₹414 Mn, resulting in an EBITDA margin of 11.1%. The fourth quarter mirrored this trend, with total operating income declining by 3.2% to ₹1,053 Mn and EBITDA dropping by 18.1% to ₹134 Mn, leading to a 12.7% EBITDA margin. The company maintained its investment in research and development, with total R&D spend reaching ₹311 Mn for FY26.

Key Highlights

1. 1

   Zim Laboratories Limited reported a full-year FY26 total operating income of ₹3,744 Mn, representing a 1.2% decline compared to FY25.

2. 2

   The company's EBITDA for FY26 decreased by 16.4% to ₹414 Mn, with the EBITDA margin contracting by 200 basis points to 11.1%.

3. 3

   For the fourth quarter of FY26, total operating income stood at ₹1,053 Mn, down by 3.2% year-over-year.

4. 4

   Q4 FY26 EBITDA saw an 18.1% drop to ₹134 Mn, and the EBITDA margin reduced by 230 basis points to 12.7%.

5. 5

   Total R&D spend for the full year FY26 amounted to ₹311 Mn, which is 8.3% of revenue, including ₹108 Mn allocated for BE studies and regulatory filings.

6. 6

   Zim Laboratories recorded a Gross Block Addition of ₹179 Mn for Capex and registrations during FY26.